CDTX – cidara therapeutics, inc. (US:NASDAQ)

News

Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com